CHMP recommends SPEVIGO® approval for generalized pustular psoriasis flare prevention in adults/adolescents.

The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a new indication for SPEVIGO® (spesolimab) injection, targeting generalized pustular psoriasis (GPP) flares prevention in adults and adolescents aged 12 and above. SPEVIGO®, the first targeted therapy for GPP, reduced GPP flare risk by 84% compared to placebo in the EFFISAYIL® 2 trial.

July 29, 2024
3 Articles